Polymyxin b in combination with enrofloxacin exerts synergistic killing against extensively drug-resistant pseudomonas aeruginosa

Yu-Wei Lin, Heidi H. Yu, Jinxin Zhao, Mei-Ling Han, Yan Zhu, Jesmin Akter, Hasini Wickremasinghe, Hasini Walpola, Veronika Wirth, Gauri G. Rao, Alan Forrest, Tony Velkov, Jian Li

Research output: Contribution to journalArticleResearchpeer-review

4 Citations (Scopus)

Abstract

Polymyxins are increasingly used as a last-resort class of antibiotics against extensively drug-resistant (XDR) Gram-negative bacteria. However, resistance to polymyxins can emerge with monotherapy. As nephrotoxicity is the major dose-limiting factor for polymyxin monotherapy, dose escalation to suppress the emergence of polymyxin resistance is not a viable option. Therefore, novel approaches are needed to preserve this last-line class of antibiotics. This study aimed to investigate the antimicrobial synergy of polymyxin B combined with enrofloxacin against Pseudomonas aeruginosa. Static time-kill studies were conducted over 24 h with polymyxin B (1 to 4 mg/liter) and enrofloxacin (1 to 4 mg/liter) alone or in combination. Additionally, in vitro one-compartment model (IVM) and hollow-fiber infection model (HFIM) experiments were performed against P. aeruginosa 12196. Polymyxin B and enrofloxacin in monotherapy were ineffective against all of the P. aeruginosa isolates examined, whereas polymyxin B-enrofloxacin in combination was synergistic against P. aeruginosa, with 2 to 4 log10 kill at 24 h in the static time-kill studies. In both IVM and HFIM, the combination was synergistic, and the bacterial counting values were below the limit of quantification on day 5 in the HFIM. A population analysis profile indicated that the combination inhibited the emergence of polymyxin resistance in P. aeruginosa 12196. The mechanism-based modeling suggests that the synergistic killing is a result of the combination of mechanistic and subpopulation synergy. Overall, this is the first preclinical study to demonstrate that the polymyxin-enrofloxacin combination is of considerable utility for the treatment of XDR P. aeruginosa infections and warrants future clinical evaluations.

Original languageEnglish
Article numbere00028-18
Number of pages13
JournalAntimicrobial Agents and Chemotherapy
Volume62
Issue number6
DOIs
Publication statusPublished - 1 Jun 2018

Keywords

  • Antibiotic combination
  • Enrofloxacin
  • Extensively drug resistant
  • Polymyxins
  • Pseudomonas aeruginosa

Cite this

Lin, Yu-Wei ; Yu, Heidi H. ; Zhao, Jinxin ; Han, Mei-Ling ; Zhu, Yan ; Akter, Jesmin ; Wickremasinghe, Hasini ; Walpola, Hasini ; Wirth, Veronika ; Rao, Gauri G. ; Forrest, Alan ; Velkov, Tony ; Li, Jian. / Polymyxin b in combination with enrofloxacin exerts synergistic killing against extensively drug-resistant pseudomonas aeruginosa. In: Antimicrobial Agents and Chemotherapy. 2018 ; Vol. 62, No. 6.
@article{c29bcd2398324ec58b8c1fc452afe813,
title = "Polymyxin b in combination with enrofloxacin exerts synergistic killing against extensively drug-resistant pseudomonas aeruginosa",
abstract = "Polymyxins are increasingly used as a last-resort class of antibiotics against extensively drug-resistant (XDR) Gram-negative bacteria. However, resistance to polymyxins can emerge with monotherapy. As nephrotoxicity is the major dose-limiting factor for polymyxin monotherapy, dose escalation to suppress the emergence of polymyxin resistance is not a viable option. Therefore, novel approaches are needed to preserve this last-line class of antibiotics. This study aimed to investigate the antimicrobial synergy of polymyxin B combined with enrofloxacin against Pseudomonas aeruginosa. Static time-kill studies were conducted over 24 h with polymyxin B (1 to 4 mg/liter) and enrofloxacin (1 to 4 mg/liter) alone or in combination. Additionally, in vitro one-compartment model (IVM) and hollow-fiber infection model (HFIM) experiments were performed against P. aeruginosa 12196. Polymyxin B and enrofloxacin in monotherapy were ineffective against all of the P. aeruginosa isolates examined, whereas polymyxin B-enrofloxacin in combination was synergistic against P. aeruginosa, with 2 to 4 log10 kill at 24 h in the static time-kill studies. In both IVM and HFIM, the combination was synergistic, and the bacterial counting values were below the limit of quantification on day 5 in the HFIM. A population analysis profile indicated that the combination inhibited the emergence of polymyxin resistance in P. aeruginosa 12196. The mechanism-based modeling suggests that the synergistic killing is a result of the combination of mechanistic and subpopulation synergy. Overall, this is the first preclinical study to demonstrate that the polymyxin-enrofloxacin combination is of considerable utility for the treatment of XDR P. aeruginosa infections and warrants future clinical evaluations.",
keywords = "Antibiotic combination, Enrofloxacin, Extensively drug resistant, Polymyxins, Pseudomonas aeruginosa",
author = "Yu-Wei Lin and Yu, {Heidi H.} and Jinxin Zhao and Mei-Ling Han and Yan Zhu and Jesmin Akter and Hasini Wickremasinghe and Hasini Walpola and Veronika Wirth and Rao, {Gauri G.} and Alan Forrest and Tony Velkov and Jian Li",
year = "2018",
month = "6",
day = "1",
doi = "10.1128/AAC.00028-18",
language = "English",
volume = "62",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "1098-6596",
publisher = "American Society for Microbiology",
number = "6",

}

Polymyxin b in combination with enrofloxacin exerts synergistic killing against extensively drug-resistant pseudomonas aeruginosa. / Lin, Yu-Wei; Yu, Heidi H.; Zhao, Jinxin; Han, Mei-Ling; Zhu, Yan; Akter, Jesmin; Wickremasinghe, Hasini; Walpola, Hasini; Wirth, Veronika; Rao, Gauri G.; Forrest, Alan; Velkov, Tony; Li, Jian.

In: Antimicrobial Agents and Chemotherapy, Vol. 62, No. 6, e00028-18, 01.06.2018.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Polymyxin b in combination with enrofloxacin exerts synergistic killing against extensively drug-resistant pseudomonas aeruginosa

AU - Lin, Yu-Wei

AU - Yu, Heidi H.

AU - Zhao, Jinxin

AU - Han, Mei-Ling

AU - Zhu, Yan

AU - Akter, Jesmin

AU - Wickremasinghe, Hasini

AU - Walpola, Hasini

AU - Wirth, Veronika

AU - Rao, Gauri G.

AU - Forrest, Alan

AU - Velkov, Tony

AU - Li, Jian

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Polymyxins are increasingly used as a last-resort class of antibiotics against extensively drug-resistant (XDR) Gram-negative bacteria. However, resistance to polymyxins can emerge with monotherapy. As nephrotoxicity is the major dose-limiting factor for polymyxin monotherapy, dose escalation to suppress the emergence of polymyxin resistance is not a viable option. Therefore, novel approaches are needed to preserve this last-line class of antibiotics. This study aimed to investigate the antimicrobial synergy of polymyxin B combined with enrofloxacin against Pseudomonas aeruginosa. Static time-kill studies were conducted over 24 h with polymyxin B (1 to 4 mg/liter) and enrofloxacin (1 to 4 mg/liter) alone or in combination. Additionally, in vitro one-compartment model (IVM) and hollow-fiber infection model (HFIM) experiments were performed against P. aeruginosa 12196. Polymyxin B and enrofloxacin in monotherapy were ineffective against all of the P. aeruginosa isolates examined, whereas polymyxin B-enrofloxacin in combination was synergistic against P. aeruginosa, with 2 to 4 log10 kill at 24 h in the static time-kill studies. In both IVM and HFIM, the combination was synergistic, and the bacterial counting values were below the limit of quantification on day 5 in the HFIM. A population analysis profile indicated that the combination inhibited the emergence of polymyxin resistance in P. aeruginosa 12196. The mechanism-based modeling suggests that the synergistic killing is a result of the combination of mechanistic and subpopulation synergy. Overall, this is the first preclinical study to demonstrate that the polymyxin-enrofloxacin combination is of considerable utility for the treatment of XDR P. aeruginosa infections and warrants future clinical evaluations.

AB - Polymyxins are increasingly used as a last-resort class of antibiotics against extensively drug-resistant (XDR) Gram-negative bacteria. However, resistance to polymyxins can emerge with monotherapy. As nephrotoxicity is the major dose-limiting factor for polymyxin monotherapy, dose escalation to suppress the emergence of polymyxin resistance is not a viable option. Therefore, novel approaches are needed to preserve this last-line class of antibiotics. This study aimed to investigate the antimicrobial synergy of polymyxin B combined with enrofloxacin against Pseudomonas aeruginosa. Static time-kill studies were conducted over 24 h with polymyxin B (1 to 4 mg/liter) and enrofloxacin (1 to 4 mg/liter) alone or in combination. Additionally, in vitro one-compartment model (IVM) and hollow-fiber infection model (HFIM) experiments were performed against P. aeruginosa 12196. Polymyxin B and enrofloxacin in monotherapy were ineffective against all of the P. aeruginosa isolates examined, whereas polymyxin B-enrofloxacin in combination was synergistic against P. aeruginosa, with 2 to 4 log10 kill at 24 h in the static time-kill studies. In both IVM and HFIM, the combination was synergistic, and the bacterial counting values were below the limit of quantification on day 5 in the HFIM. A population analysis profile indicated that the combination inhibited the emergence of polymyxin resistance in P. aeruginosa 12196. The mechanism-based modeling suggests that the synergistic killing is a result of the combination of mechanistic and subpopulation synergy. Overall, this is the first preclinical study to demonstrate that the polymyxin-enrofloxacin combination is of considerable utility for the treatment of XDR P. aeruginosa infections and warrants future clinical evaluations.

KW - Antibiotic combination

KW - Enrofloxacin

KW - Extensively drug resistant

KW - Polymyxins

KW - Pseudomonas aeruginosa

UR - http://www.scopus.com/inward/record.url?scp=85047649622&partnerID=8YFLogxK

U2 - 10.1128/AAC.00028-18

DO - 10.1128/AAC.00028-18

M3 - Article

AN - SCOPUS:85047649622

VL - 62

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 1098-6596

IS - 6

M1 - e00028-18

ER -